The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer.

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer.

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

Researchers are enrolling patients in a trial of ELI-00 7P — a vaccine to treat KRAS-mutant cancer.

Patients with advanced gynecologic cancer given IMNN-001 with presurgical chemotherapy tended to live nearly a year longer.

23andMe and 20 lung cancer advocacy organizations are working to improve lung cancer detection, risk reduction and care.

Sequencing the novel drug, THIO, with Libtayo tended to be tolerable in patients with non-small cell lung cancer, recent research showed.

A novel intratumoral treatment was administered to the first patient in a phase 3 trial for certain patients with metastatic soft tissue sarcoma.

Two immune checkpoint inhibitors are being evaluated together in a phase 1 trial for certain patients with advanced solid tumors.

A new arm of a clinical trial will investigate (Z)-endoxifen plus Verzenio in patients with ER-positive, HER2-negative breast cancer.

A patient received a dose of the novel menin inhibitor, ziftomenib, plus Xospata in a phase 1 trial for patients with AML.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer.

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

The novel drug, IDP-023, is being investigated in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma.

A phase 2 trial is evaluating ELI-002 7P, a novel cancer vaccine, for the treatment of patients with KRAS-mutant pancreatic cancer.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS.

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.

B42-001, a novel CAR-T cell therapy, will be tested in a phase 1 trial for the treatment of patients with BT-001—positive solid cancers.

A phase 1 trial is being conducted to evaluate the combination of PT886 and Keytruda in patients with claudin 18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinomas.

A new phase 1 trial is testing their first patients with STAR-LLD in the treatment of patients with multiple myeloma.

The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors.

A phase 1 clinical trial just launched and will test the novel agent, CLN-978, for relapsed/refractory B-cell non-Hodgkin lymphoma.